SEMA6B and neoplasm: The present study, through bioinformatic analysis on GTEx and clinical sample RNA-seq datasets, provided evidence that SEMA6B may be a potential informative biomarker for patients with THCA, suggesting its diagnostic and prognostic value, not only in general tumor-bearing population, but also in subgroup of patients with specific disease stage, pathological type and metastatic state.